Pediatric Anti-NMDA Receptor Encephalitis Treatment in China: A Survey of 200 Pediatric Neurologists
Pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a rare autoimmune brain condition that can cause seizures, confusion, movement disorders, and behavioral changes in children. While immunotherapy can improve outcomes, there’s no global standardized treatment protocol—especially for kids in China, where previous international surveys hadn’t focused on local practices. To bridge this gap, researchers from top Chinese hospitals surveyed senior pediatric neurologists to map real-world treatment strategies and identify areas for better guidelines.
The Study: What They Wanted to Learn
Previous surveys (by Kahn et al. in 2017 and Bartolini et al. in 2017) looked at anti-NMDAR encephalitis treatment worldwide but missed key details:
- How doctors use the modified Rankin Scale (mRS)—a tool to measure disability (0 = no disability, 5 = severe disability)—to guide treatment.
- Dosing and duration of common drugs like oral prednisone.
- Whether to adjust rituximab (a second-line drug) based on CD19+ B cells—immune cells the drug targets, which can signal dosing needs.
- Long-term immunosuppression for relapse prevention.
- When to stop immunotherapy.
To answer these, the Chinese team surveyed 200 senior pediatric neurologists from 125 hospitals—most were chief doctors who treated 1–9 cases of pediatric anti-NMDAR encephalitis yearly. Their findings, published in the Chinese Medical Journal in 2021, offer a rare window into how doctors in China manage this complex condition.
Key Findings: How Chinese Doctors Treat Pediatric Anti-NMDAR Encephalitis
1. First-Line Treatment: Steroids + IVIG Over Plasma Exchange
Most doctors chose a combination of methylprednisolone (a steroid) pulse therapy and intravenous immunoglobulin (IVIG) as first-line treatment—more than plasma exchange (which filters blood to remove harmful antibodies). Plasma exchange was less common because it’s invasive, especially for young kids.
- Methylprednisolone pulse duration: 3–5 days (most common).
- Oral prednisone tapering: No clear agreement—doctors were split on how long to continue lower-dose steroids after the pulse, a gap that could affect relapse risk.
- mRS use: Few doctors used the mRS to decide when to start first-line therapy. Instead, they relied on clinical symptoms (like seizures or confusion) rather than blood/CSF test results—a finding consistent with the 2017 Kahn et al. survey.
2. Second-Line Treatment: Rituximab Is Top Choice—But Timing Varies
When first-line treatment failed, 75% of doctors turned to rituximab (a drug that targets immune cells) as second-line therapy—followed by cyclophosphamide.
- Timing: Half of doctors waited 14–28 days after starting first-line treatment to switch to second-line. Previous surveys found shorter (under 2 weeks) or longer (1–2 months) intervals, highlighting global uncertainty about “when” to escalate care.
- mRS cut-off: Most used an mRS score of 3 (moderate disability, e.g., needing help walking) to decide when to start second-line therapy.
- Rituximab dosing: Most prescribed a standard dose instead of adjusting for CD19+ B cell counts. Monitoring these cells could reduce side effects (like infections or low blood counts), but this practice isn’t widespread in China yet.
A 2013 Lancet Neurology study—one of the largest on anti-NMDAR encephalitis—supported rituximab’s use: it linked the drug to better outcomes and fewer relapses when used second-line.
3. Long-Term Immunosuppression: Not Routine, But Used for Relapse Prevention
Over half of doctors said they don’t routinely use long-term immunosuppressive drugs (like mycophenolate mofetil or azathioprine) to prevent relapses. When they did:
- Top choice: Mycophenolate mofetil (followed by azathioprine).
- Duration: Most prescribed it for 6–12 months.
This aligns with a 2019 European Journal of Paediatric Neurology review, which found these drugs are used but with no clear consensus on how long to continue them.
4. When to Stop Immunotherapy: Clinical Improvement First
Doctors mostly stopped treatment when a child’s symptoms improved (e.g., fewer seizures, better thinking skills). Next came:
- Normalized CSF/serum anti-NMDAR antibodies.
- Improved brain MRI or EEG results.
- Lower mRS score.
Limitations: What the Study Didn’t Cover
The survey had gaps:
- China-only: Results might not apply to other countries with different healthcare systems.
- Sample bias: The 200 doctors may not represent all pediatric neurologists in China.
- No alternative second-line: The team didn’t ask about treatments for doctors without access to rituximab or cyclophosphamide.
What This Means for Kids With Anti-NMDAR Encephalitis
The study is a big step toward standardized guidelines for China. Here’s what doctors and families can take away:
- Consensus on core treatments: First-line (methylprednisolone + IVIG) and second-line (rituximab) are widely agreed upon—aligning with global research.
- Big questions remain: We still don’t know the exact duration of first-line therapy, how to safely taper oral prednisone, or when to start second-line treatment. Long-term immunosuppression also needs more research.
- CD19+ monitoring matters: The team emphasized that tracking CD19+ B cells could help adjust rituximab doses and reduce side effects—a practice that should become more common.
The Bottom Line
Pediatric anti-NMDAR encephalitis is complex, but this survey helps doctors move from “best guess” to evidence-based care. By combining local data with international findings, it’s a key step toward better outcomes for kids in China. Until more clinical trials answer lingering questions, doctors will rely on experience and emerging evidence to treat this rare condition.
The study was led by Xiao-Shuang Cao (Department of Pediatrics, Xiangya Hospital, Central South University), Miriam Kessi (Hunan Intellectual and Developmental Disabilities Research Center), Tao-Yun Ji (Department of Pediatrics, Peking University First Hospital), Yu-Wu Jiang (Division of Pediatric Neurology, Peking University First Hospital), Fei Yin (Xiangya Hospital), and Jing Peng (Xiangya Hospital and Hunan Intellectual and Developmental Disabilities Research Center).
doi.org/10.1097/CM9.0000000000001308
Was this helpful?
0 / 0